<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00770133</url>
  </required_header>
  <id_info>
    <org_study_id>572</org_study_id>
    <nct_id>NCT00770133</nct_id>
  </id_info>
  <brief_title>Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.</brief_title>
  <official_title>A Multi-center, Double-masked, Randomized, Placebo-controlled Evaluation of the Onset and Duration of Action of KetoNaph Ophthalmic Solution in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline&#xD;
      ophthalmic solution compared to vehicle and its individual components in alleviating the&#xD;
      signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>3, 5, and 7 minutes post challenge at 14 days</time_frame>
    <description>Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0=None and 4.0=Incapacitating itch with an irresistible urge to rub</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosis</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eyelid Swelling</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Lid swelling was evaluated by the participant at 7, 15, and 20 minutes post challenge on a 0-3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0=None and 3.0=Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With hTearing</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Tearing was evaluated by the participant at 7, 15, and 20 minutes post challenge. Tearing was recorded as either absent or present.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Eyes With Ocular Mucus Discharge</measure>
    <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
    <description>Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <arm_group>
    <arm_group_label>Ketotifen/naphazoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naphazoline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketotifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen/naphazoline</intervention_name>
    <description>One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
    <arm_group_label>Ketotifen/naphazoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naphazoline</intervention_name>
    <description>One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
    <arm_group_label>Naphazoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketotifen</intervention_name>
    <description>One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
    <arm_group_label>Ketotifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive history of ocular allergies and positive skin test reaction to cat hair, cat&#xD;
             dander, grasses, ragweed, and/or trees within the past 24 months.&#xD;
&#xD;
          -  Calculated best-corrected visual acuity of 0.7 logMAR or better in each eye as&#xD;
             measured using the ETDRS chart.&#xD;
&#xD;
          -  Positive bilateral conjunctival allergen challenge(CAC) reaction within 10 minutes of&#xD;
             instillation of the last titration of allergen at visit 1.&#xD;
&#xD;
          -  Positive bilateral CAC reaction for at least 2 out of 3 time points at visit 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contraindications or sensitivities to the study medication or its components.&#xD;
&#xD;
          -  Any ocular condition that, in the opinion of the investigator, could affect the&#xD;
             subjects safety or trial parameters.&#xD;
&#xD;
          -  Use of disallowed medications during the period indicated prior to study enrollment or&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Trusso</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Consultants, Inc.</name>
      <address>
        <city>North Andover</city>
        <state>Massachusetts</state>
        <zip>01845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <results_first_submitted>August 24, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 27, 2020</results_first_posted>
  <disposition_first_submitted>April 26, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 26, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 3, 2011</disposition_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketotifen</mesh_term>
    <mesh_term>Naphazoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>There were 70 eyes in the KetoNaph group, 72 in the ketotifen group, 70 in the naphazoline group, and 70 in the vehicle group, for a total of 282 eyes (141 subjects).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ketotifen/Naphazoline</title>
          <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
        </group>
        <group group_id="P2">
          <title>Ketotifen</title>
          <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="P3">
          <title>Naphazoline</title>
          <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="P4">
          <title>Vehicle</title>
          <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketotifen/Naphazoline</title>
          <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
        </group>
        <group group_id="B2">
          <title>Ketotifen</title>
          <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="B3">
          <title>Naphazoline</title>
          <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="B4">
          <title>Vehicle</title>
          <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="35"/>
            <count group_id="B5" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.1" lower_limit="15" upper_limit="71"/>
                    <measurement group_id="B2" value="40.7" lower_limit="15" upper_limit="71"/>
                    <measurement group_id="B3" value="38.2" lower_limit="16" upper_limit="76"/>
                    <measurement group_id="B4" value="38.4" lower_limit="16" upper_limit="76"/>
                    <measurement group_id="B5" value="38.4" lower_limit="15" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching</title>
        <description>Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0=None and 4.0=Incapacitating itch with an irresistible urge to rub</description>
        <time_frame>3, 5, and 7 minutes post challenge at 14 days</time_frame>
        <population>The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challeng assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Ocular itching was evaluated by the participant at 3, 5, and 7 minutes post challenge. Assessments were made using a 0-4 numerical analog scale, allowing 0.5-unit increments (but disallowing 0.25-unit increments), where: 0.0=None and 4.0=Incapacitating itch with an irresistible urge to rub</description>
          <population>The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challeng assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.62"/>
                    <measurement group_id="O2" value="0.40" spread="0.65"/>
                    <measurement group_id="O3" value="1.60" spread="0.92"/>
                    <measurement group_id="O4" value="1.81" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.76"/>
                    <measurement group_id="O2" value="0.59" spread="0.79"/>
                    <measurement group_id="O3" value="1.67" spread="1.01"/>
                    <measurement group_id="O4" value="1.96" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.83"/>
                    <measurement group_id="O2" value="0.56" spread="0.87"/>
                    <measurement group_id="O3" value="1.54" spread="0.96"/>
                    <measurement group_id="O4" value="1.84" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness</title>
        <description>Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challeng assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness</title>
          <description>Conjunctival hyperemia was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were completed using a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
          <population>The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challeng assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challeng</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.87"/>
                    <measurement group_id="O2" value="1.49" spread="0.83"/>
                    <measurement group_id="O3" value="1.63" spread="0.84"/>
                    <measurement group_id="O4" value="2.06" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.00"/>
                    <measurement group_id="O2" value="1.80" spread="0.87"/>
                    <measurement group_id="O3" value="1.69" spread="0.89"/>
                    <measurement group_id="O4" value="2.26" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.02"/>
                    <measurement group_id="O2" value="1.88" spread="0.89"/>
                    <measurement group_id="O3" value="1.57" spread="0.92"/>
                    <measurement group_id="O4" value="2.18" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness</title>
        <description>Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness</title>
          <description>Ciliary hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.86"/>
                    <measurement group_id="O2" value="1.33" spread="0.88"/>
                    <measurement group_id="O3" value="1.49" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="1.05"/>
                    <measurement group_id="O2" value="1.76" spread="0.91"/>
                    <measurement group_id="O3" value="1.59" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="1.03"/>
                    <measurement group_id="O2" value="1.76" spread="0.94"/>
                    <measurement group_id="O3" value="1.54" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness</title>
        <description>Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness</title>
          <description>Episcleral hyperemia (redness) was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Assessments were made using the same 0-4 scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.89"/>
                    <measurement group_id="O2" value="1.51" spread="0.85"/>
                    <measurement group_id="O3" value="1.65" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.01"/>
                    <measurement group_id="O2" value="1.76" spread="0.88"/>
                    <measurement group_id="O3" value="1.68" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.03"/>
                    <measurement group_id="O2" value="1.88" spread="0.90"/>
                    <measurement group_id="O3" value="1.60" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chemosis</title>
        <description>Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Chemosis</title>
          <description>Chemosis was evaluated by the Investigator at 7, 15, and 20 minutes post challenge on a 0-4 numerical analog scale, allowing 0.5-unit increments, where: 0.0=None and 4.0=Extremely severe.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.33"/>
                    <measurement group_id="O2" value="0.28" spread="0.30"/>
                    <measurement group_id="O3" value="0.39" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.38"/>
                    <measurement group_id="O2" value="0.46" spread="0.47"/>
                    <measurement group_id="O3" value="0.54" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.41"/>
                    <measurement group_id="O2" value="0.49" spread="0.46"/>
                    <measurement group_id="O3" value="0.54" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eyelid Swelling</title>
        <description>Lid swelling was evaluated by the participant at 7, 15, and 20 minutes post challenge on a 0-3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0=None and 3.0=Severe.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Eyelid Swelling</title>
          <description>Lid swelling was evaluated by the participant at 7, 15, and 20 minutes post challenge on a 0-3 numerical analog scale, with 0.5-unit increments disallowed, where: 0.0=None and 3.0=Severe.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.4"/>
                    <measurement group_id="O2" value="0.2" spread="0.4"/>
                    <measurement group_id="O3" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.2" spread="0.4"/>
                    <measurement group_id="O3" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.2" spread="0.4"/>
                    <measurement group_id="O3" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With hTearing</title>
        <description>Tearing was evaluated by the participant at 7, 15, and 20 minutes post challenge. Tearing was recorded as either absent or present.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With hTearing</title>
          <description>Tearing was evaluated by the participant at 7, 15, and 20 minutes post challenge. Tearing was recorded as either absent or present.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Eyes With Ocular Mucus Discharge</title>
        <description>Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present.</description>
        <time_frame>7, 15, and 20 minutes post challenge at 14 days</time_frame>
        <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ketotifen/Naphazoline</title>
            <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
          </group>
          <group group_id="O2">
            <title>Ketotifen</title>
            <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O3">
            <title>Naphazoline</title>
            <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
          </group>
          <group group_id="O4">
            <title>Vehicle</title>
            <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Ocular Mucus Discharge</title>
          <description>Ocular mucous discharge was evaluated by the Investigator at 7, 15, and 20 minutes post challenge. Mucous discharged was recorded as either absent or present.</description>
          <population>This outcome measure was not assessed for the Vehicle group. The intent to treat population consisted of participants who were randomized, received investigational treatment, and had at least 1 post-challenge assessment.</population>
          <units>eyes</units>
          <param>Count of Units</param>
          <units_analyzed>eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>7 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minutes post-challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ketotifen/Naphazoline</title>
          <description>Ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen/naphazoline: One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.</description>
        </group>
        <group group_id="E2">
          <title>Ketotifen</title>
          <description>Ketotifen ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Ketotifen: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="E3">
          <title>Naphazoline</title>
          <description>Naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Naphazoline: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.</description>
        </group>
        <group group_id="E4">
          <title>Vehicle</title>
          <description>Vehicle of ketotifen/naphazoline ophthalmic solution administered in either the right eye, left eye or both eyes at visit 3 and visit 4.&#xD;
Vehicle: One drop of vehicle ophthalmic solution at visit 3 and visit 4.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <phone>908-300-9920</phone>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

